Daesung Microbiological Labs. Co., Ltd.

KOSDAQ:A036480 Stock Report

Market Cap: ₩23.7b

Daesung Microbiological Labs Past Earnings Performance

Past criteria checks 2/6

Daesung Microbiological Labs's earnings have been declining at an average annual rate of -33.1%, while the Biotechs industry saw earnings growing at 15.2% annually. Revenues have been growing at an average rate of 1% per year. Daesung Microbiological Labs's return on equity is 1.9%, and it has net margins of 2.5%.

Key information

-33.11%

Earnings growth rate

-33.11%

EPS growth rate

Biotechs Industry Growth11.70%
Revenue growth rate0.99%
Return on equity1.87%
Net Margin2.53%
Last Earnings Update31 Mar 2026

Recent past performance updates

Analysis Article • Feb 17

We're Not Counting On Daesung Microbiological Labs (KOSDAQ:036480) To Sustain Its Statutory Profitability

It might be old fashioned, but we really like to invest in companies that make a profit, each and every year. That...
Analysis Article • Nov 19

Here's Why We Don't Think Daesung Microbiological Labs's (KOSDAQ:036480) Statutory Earnings Reflect Its Underlying Earnings Potential

Statistically speaking, it is less risky to invest in profitable companies than in unprofitable ones. However...

Recent updates

Analysis Article • Aug 06

Daesung Microbiological Labs (KOSDAQ:036480) Is Carrying A Fair Bit Of Debt

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • May 08

Is Daesung Microbiological Labs (KOSDAQ:036480) Using Too Much Debt?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article • Mar 15

Is The Market Rewarding Daesung Microbiological Labs. Co., Ltd. (KOSDAQ:036480) With A Negative Sentiment As A Result Of Its Mixed Fundamentals?

Daesung Microbiological Labs (KOSDAQ:036480) has had a rough month with its share price down 9.5%. We, however decided...
Analysis Article • Feb 17

We're Not Counting On Daesung Microbiological Labs (KOSDAQ:036480) To Sustain Its Statutory Profitability

It might be old fashioned, but we really like to invest in companies that make a profit, each and every year. That...
Analysis Article • Jan 21

Is Daesung Microbiological Labs (KOSDAQ:036480) A Risky Investment?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Analysis Article • Dec 31

Update: Daesung Microbiological Labs (KOSDAQ:036480) Stock Gained 83% In The Last Five Years

Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the...
Analysis Article • Dec 10

Daesung Microbiological Labs. Co., Ltd. (KOSDAQ:036480) Is Up But Financials Look Inconsistent: Which Way Is The Stock Headed?

Daesung Microbiological Labs' (KOSDAQ:036480) stock is up by 4.3% over the past month. However, the company's...
Analysis Article • Nov 19

Here's Why We Don't Think Daesung Microbiological Labs's (KOSDAQ:036480) Statutory Earnings Reflect Its Underlying Earnings Potential

Statistically speaking, it is less risky to invest in profitable companies than in unprofitable ones. However...

Revenue & Expenses Breakdown

How Daesung Microbiological Labs makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A036480 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 2625,8706545,1820
31 Dec 2525,9895985,0690
30 Sep 2525,8621,3435,0450
30 Jun 2524,494-7375,0880
31 Mar 2523,412-1,7194,9530
31 Dec 2423,804-1,7694,9430
30 Sep 2424,164-2,7994,7570
30 Jun 2424,009-2,6024,6890
31 Mar 2425,423-1,1474,9510
31 Dec 2325,562-6804,8160
30 Sep 2325,502-6744,6790
30 Jun 2324,7964414,6220
31 Mar 2324,8711274,3040
31 Dec 2225,5001,7034,3840
30 Sep 2225,1672,4934,5210
30 Jun 2225,6492,1744,6620
31 Mar 2224,7602,5684,6760
31 Dec 2123,9978664,7060
30 Sep 2123,179-2655,2210
30 Jun 2123,3743355,3500
31 Mar 2123,6167665,2370
31 Dec 2024,8011,5195,4730
30 Sep 2025,4082,0584,7470
30 Jun 2024,5151,8824,4360
31 Mar 2025,8682,5104,6840
31 Dec 1925,1342,4714,2960
30 Sep 1924,9183,5664,2950
30 Jun 1926,5444,2554,3360
31 Mar 1925,4833,6224,2380
31 Dec 1825,0973,1704,1850
30 Sep 1824,1592,0984,1930
30 Jun 1824,0881,6544,3380
31 Mar 1824,1511,6864,4210
31 Dec 1724,0431,5584,6500
30 Sep 1726,0222,6114,9330
30 Jun 1727,3533,0894,8760
31 Mar 1728,5493,4754,7760
31 Dec 1630,8014,4954,6820
30 Sep 1631,8054,5834,4650
30 Jun 1629,8684,1674,4550
31 Mar 1631,0864,2134,4510
31 Dec 1531,0264,5504,3800
30 Sep 1529,4293,7864,3880

Quality Earnings: A036480 has high quality earnings.

Growing Profit Margin: A036480 became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A036480's earnings have declined by 33.1% per year over the past 5 years.

Accelerating Growth: A036480 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: A036480 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (22.6%).

Return on Equity

High ROE: A036480's Return on Equity (1.9%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/05 03:21
End of Day Share Price 2026/08/05 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Daesung Microbiological Labs. Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.